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Purpose: Substantial heterogeneity exists in reported kidney function decline in pre-dialysis 
chronic kidney disease (CKD). By design, kidney function decline can be studied in CKD 3–5 
cohorts or dialysis-based studies. In the latter, patients are selected based on the fact that they 
initiated dialysis, possibly leading to an overestimation of the true underlying kidney function 
decline in the pre-dialysis period. We performed a systematic review and meta-analysis to 
compare the kidney function decline during pre-dialysis in CKD stage 3–5 patients, in these 
two different study types.
Patients and methods: We searched PubMed, EMBASE, Web of Science and Cochrane 
to identify eligible studies reporting an estimated glomerular filtration rate (eGFR) decline 
(mL/min/1.73 m2) in adult pre-dialysis CKD patients. Random-effects meta-analysis was per-
formed to obtain weighted mean annual eGFR decline.
Results: We included 60 studies (43 CKD 3–5 cohorts and 17 dialysis-based studies). The 
meta-analysis yielded a weighted annual mean (95% CI) eGFR decline during pre-dialysis of 
2.4 (95% CI: 2.2, 2.6) mL/min/1.73 m2 in CKD 3–5 cohorts compared to 8.5 (95% CI: 6.8, 
10.1) in dialysis-based studies (difference 6.0 [95% CI: 4.8, 7.2]).
Conclusion: To conclude, dialysis-based studies report faster mean annual eGFR decline during 
pre-dialysis than CKD 3–5 cohorts. Thus, eGFR decline data from CKD 3–5 cohorts should be 
used to guide clinical decision making in CKD patients and for power calculations in random-
ized controlled trials with CKD progression during pre-dialysis as the outcome.
Keywords: meta-analysis, systematic review, kidney function decline, dialysis, chronic kidney 
disease, pre-dialysis, CKD progression
Introduction
Chronic kidney disease (CKD) is a major public health problem worldwide with poor 
clinical outcomes.1 Prevalence and incidence of CKD are increasing rapidly, and the 
demand for pre-dialysis care is growing.2 Pre-dialysis care aims to slow down decline 
in kidney function and to prepare patients for their potential start of renal replacement 
therapy (RRT; dialysis and kidney transplantation). Detailed knowledge of the rate of 
kidney function decline in moderate to advanced CKD patients before the start of RRT 
could guide clinical decision making and anticipate treatment choices and priorities.3–5
Studies among CKD patients point to substantial heterogeneity in kidney function 
decline during the pre-dialysis period.3,6–12 The estimated glomerular filtration rate 
(eGFR) is commonly used as a measure for renal insufficiency in CKD patients during 
the pre-dialysis period. Kidney function decline during the pre-dialysis trajectory can 
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be studied in CKD 3–5 cohorts, or in a subgroup of patients 
who initiated dialysis at some point, dialysis-based studies 
(Figure S1).3,11–19 These populations differ with regard to 
patient selection. In CKD 3–5 cohorts, patients are followed 
from a certain point in the pre-dialysis phase and an overall 
eGFR decline is reported, while not all patients end up on 
RRT. When patients on dialysis are selected (dialysis-based 
studies), eGFR decline is determined in a specified period 
prior to this dialysis initiation. As a consequence, we hypoth-
esize that decline rates obtained from dialysis-based studies 
overestimate the true underlying kidney function decline in 
the overall pre-dialysis CKD population (see Supplementary 
material 1 for a more detailed theoretical explanation).
A comprehensive characterization of the actual magnitude 
of annual kidney function decline during the pre-dialysis 
period is essential for clinical decision making in the man-
agement of CKD patients, including the anticipation of 
dialysis onset. It is also important for power calculations of 
randomized controlled trials aimed to study kidney disease 
progression. Therefore, we aimed to perform a systematic 
review and meta-(regression) analysis to assess and compare 
kidney function decline during the pre-dialysis trajectory 
between CKD 3–5 cohorts and dialysis-based studies.
Patients and methods
Eligibility criteria
We searched for studies reporting kidney function decline 
in the pre-dialysis period (CKD stage 3–5 [eGFR <60 mL/
min/1.73 m2]) in adult populations. The following inclusion 
criteria were applied: studies which defined and reported 
kidney function decline as eGFR or creatinine clearance 
were eligible, comprising a four-variable modification of 
diet in renal disease (MDRD), Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation or 
Cockcroft–Gault formula.20–24 In case of multiple studies 
describing the same study population and study outcome, 
the study with the most complete data was selected. Only 
studies comprising a population of 50 patients or more were 
included. Meeting abstracts, case reports, editorials and 
animal studies were excluded. Also, articles in languages 
other than English, French, German, Dutch or Spanish 
were not eligible.
search strategy
We searched in PubMed, EMBASE, Web of Science and the 
Cochrane Database for eligible literature published between 
January 2000 and December 2016 (both published and 
epubs published in advance, Supplementary  material 2). 
 Furthermore, references of key articles were searched to 
 identify potentially relevant studies. The systematic review 
was conducted according to the PRISMA guidelines.25
Data extraction
Studies retrieved from the search strategy were entered 
into reference manager software (EndNote X7) and were 
screened based on title and abstract. Potentially relevant 
studies were retrieved for detailed assessment. For eligible 
studies, data were independently extracted by two reviewers 
(CJJ and CCEH). Disagreements between reviewers were 
resolved by consensus, or by a third reviewer (OMD) in case 
of remaining doubt.
For all included studies, the following data were extracted 
and entered into an electronic database: first author and year 
of publication, number of participants and population stud-
ied, setting (e.g., referral center/name of study and country), 
mean age, proportion of male and diabetes, kidney function 
measure (e.g., MDRD, CKD-EPI, Cockcroft–Gault formula), 
duration of pre-dialysis period, mean baseline eGFR and 
unadjusted rates of estimated annual kidney function decline 
(mL/min/1.73 m2).
For CKD 3–5 cohorts, we extracted data on the number/
proportion of patients lost to follow-up and the proportion/
number of patients who started dialysis or died before the 
end of the study. When CKD 3–5 cohorts reported both an 
overall kidney function decline rate during the pre-dialysis 
period and a separate kidney function decline for patients 
starting dialysis, the overall decline of the CKD 3–5 cohort 
was extracted. In case no patient in the CKD 3–5 cohorts 
reached dialysis/RRT, these cohorts were excluded and the 
length of follow-up during the pre-dialysis period was con-
sidered to be too short.
For dialysis-based studies, we also extracted data on 
the value of kidney function at the moment of dialysis 
initiation. For these studies, loss to follow-up was not appli-
cable. Noteworthy, the unit of eGFR values is reported as 
mL/min/1.73 m2, which is correct using the MDRD or 
CKD-EPI equation. However, the Cockcroft–Gault for-
mula estimates the creatinine clearance and is expressed in 
mL/min, without correction for body surface area. The 
creatinine clearance exceeds the GFR because creatinine is 
also secreted by the proximal tubule as well as filtered by 
the glomerulus. For the sake of readability, we have chosen 
to report all eGFR and creatinine clearance values as mL/
min/1.73 m2 for consistency, and because only a few studies 
reported the creatinine clearance values based on the Cock-
croft–Gault formula.
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risk of bias assessment
Risk of bias assessment focused on design elements that 
could potentially bias the assessment of kidney function 
decline in CKD patients during the pre-dialysis period: 
1. Adequacy of measurement of kidney function decline. 
The CKD-EPI and MDRD equation were considered 
adequate methods for measurement of eGFR. The Cock-
croft–Gault formula was considered high risk of bias.23,26
2. A proportion of loss to follow-up <10% was considered 
low risk of bias (CKD 3–5 cohorts).
3. Selection of patients: Inclusion of consecutive CKD 
3–5 or dialysis patients was considered adequate. As an 
alternative, a random sample of all CKD 3–5 or dialysis 
patients was also considered adequate.
Elements of risk of bias assessment and potential differ-
ences of these elements between studies were used to explore 
potential between-study heterogeneity. Studies with low risk 
of bias assessment for all elements were rated as low risk 
of bias overall. Because only two of these three elements 
applied to dialysis-based studies, risk of bias assessment 
was repeated for CKD 3–5 cohorts using only these two 
selection criteria.
statistical analysis
The main outcome of this meta-analysis was the weighted 
annual eGFR decline. Results were presented separately 
for CKD 3–5 cohorts and dialysis-based studies. When a 
monthly kidney function decline was reported, the decline 
rate was multiplied by 12 to estimate the annual decline rate. 
For papers presenting results as median with interquartile 
range, we recalculated this to the accompanying mean with 
SD.27,28 Furthermore, in case a paper provided separate kidney 
function declines for subgroups and no decline rate for the 
whole study population, we calculated a weighted mean with 
a pooled SD in a fixed-effect model.28 For the included stud-
ies reporting no kidney function decline, the kidney function 
values (including variance) at the start and end of follow-up/
at dialysis initiation were used to estimate an annual mean 
decline rate with pooled SD.
Meta-analysis was performed using the DerSimonian and 
Laird method.29 Given the expected clinical heterogeneity, a 
random-effects model was performed to take the between-
study variation into account and no fixed-effects analysis 
was performed (unless less than five studies presented data 
for a specific outcome). Between-study heterogeneity was 
estimated using the I2 statistic.28 For the risk of bias assess-
ment, a meta-analysis was also performed for subgroups 
according to the risk of bias status for both CKD 3–5 cohorts 
and dialysis-based studies.
Several preplanned univariate random-effects meta-
regression analyses were performed. First, the annual eGFR 
decline from CKD 3–5 cohorts and dialysis-based studies was 
compared. Sources of heterogeneity for different reported 
mean annual eGFR decline rates were identified in CKD 3–5 
cohorts, as these studies better reflect an inception cohort 
(Supplementary material 1). We investigated the association 
between the mean eGFR decline and the proportion of patients 
with diabetes in the study population, as diabetes is known to 
increase kidney function decline.30 Furthermore, we investi-
gated the association between the mean eGFR decline and the 
proportion of males in the study population, given the exist-
ing paradox that CKD 3–5 is more prevalent among women, 
although women are less likely to start dialysis.31 Another 
important source of heterogeneity might be the nonlinear 
kidney function decline over time.3,32–34 To test whether the 
linearity assumption was violated, we performed univariate 
random-effects meta-regression analysis between the annual 
eGFR decline and two explanatory variables: duration of 
pre-dialysis period and mean baseline eGFR of the study 
population. If either of these associations was significant, this 
could be explained by a violation of the linearity assumption. 
To investigate the presence of potential publication bias, we 
assessed the association between the study size and the mag-
nitude of reported eGFR decline by investigating the presence 
of funnel plot asymmetry, using Egger’s test.35
Several sensitivity analyses were performed to validate 
the robustness of the results. Since random-effects models 
fitted by the DerSimonian and Laird method could negatively 
bias the between-study variance, meta-analysis was also 
fitted by restricted maximum likelihood.29,36,37 Furthermore, 
in CKD 3–5 cohorts, a stratified meta-analysis according 
to CKD stages, based on the mean baseline eGFR of each 
cohort, was performed. We did not perform subgroup analy-
ses to assess whether or not the slope of decline in eGFR and 
creatinine clearance was different between the three formulas 
(i.e., MDRD versus CKD-EPI, and Cockcroft–Gault versus 
MDRD and CKD-EPI) or primary kidney disease, due to 
small subgroups or lack of information. Statistical analyses 
were performed with Stata Statistical Software 14.0 (Stata-
Corp LP, College Station, TX, USA).
Results
search results
We identif ied 1231 unique publications by searching 
PubMed, EMBASE, Cochrane Database, Web of  Science 
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and by screening reference lists of included articles 
(n=60). After exclusion of 1,143 publications by screen-
ing of title and abstract, 88 publications were retrieved for 
detailed assessment, of which 60 fulfilled the inclusion 
criteria. To avoid multiple inclusions of the same study 
participants and the same study outcome, we excluded 10 
publications originating from the same study populations 
 (Supplementary material 3) and included the publication 
with the most complete data. Of the 60 included publica-
tions, 43 studies presented data based on CKD 3–5 cohorts 
and 17 studies presented data based on dialysis-based 
studies (Figure 1).
study characteristics
Study characteristics of the 60 included studies are sum-
marized in Table 1. In most studies, the kidney function 
measure during the pre-dialysis period was based on an 
MDRD equation (31 CKD 3–5 cohorts and 10 dialysis-
based studies). In total, only six studies used the CKD-EPI 
equation and three studies used the Cockcroft–Gault equa-
tion. In CKD 3–5 cohorts, the mean pre-dialysis follow-up 
period ranged from 0.4 to 8.2 years and the mean baseline 
eGFR was between 10 and 45 mL/min/1.73 m2. Individual 
study characteristics of the included studies are shown in 
Tables S1 and S2.
risk of bias assessment
The risk of bias assessment is summarized in Table S3. 
Only three studies used the Cockcroft–Gault formula (two 
CKD 3–5 cohorts and one dialysis-based study). In CKD 
3–5 cohorts, the percentage loss to follow-up ranged from 
1% to 41%. Twelve studies had a loss to follow-up of <10% 
(low risk of bias), and nine studies had a loss to follow-up 
of >10%; in most studies, the percentage loss to follow-up 
was unclear. For 19 CKD 3–5 cohorts and 10 dialysis-based 
studies, consecutive or random patient sampling was applied. 
However, the sampling method was unclear for most studies.
annual egFr decline in CKD 3–5 versus 
dialysis-based studies
In a random-effects meta-analysis, the weighted mean annual 
eGFR decline was 2.4 (95% CI: 2.2, 2.6; I2 99.1%) and 
8.5 (95% CI: 6.8, 10.1; I2 99.8%) mL/min/1.73 m2 in CKD 
3–5 cohorts and dialysis-based studies, respectively (Figure 2).
Identification of sources of heterogeneity 
using meta-regression analysis
Univariate meta-regression analysis showed a large difference 
in kidney function decline between CKD 3–5 cohorts and 
dialysis-based studies: difference 5.99 mL/min/1.73 m2/year, 
(95% CI: 4.80, 7.19). It is important to identify which cohort 
PubMed
(n=799)
Unique articles
screened (n=1,231)
Full-text articles
assessed for
eligibility (n=88)
In
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Id
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n
CKD 3-5 cohorts (n=43)
dialysis-based studies (n=17)
Full-text articles excluded (n=28)
10  Multiple articles based on same cohorts and outcome
7    No continous eGFR decline
5    CKD 3–5 patients with eGFR decline without reaching dialysis
4    No eGFR available (i.e., mGFR or serum creatinine levels)
2    Available eGFR value without variance and no values with
      variance available at start and end of follow-up to subtract
      decline 
Articles excluded based on title
and abstract (n=1,143)
EMBASE
(n=1,006)
Web of Science
(n=512)
Cochrane
(n=116)
Publications identified
through reference list
searching (n=122)
Figure 1 Flow chart for the study selection of publications on kidney function decline during the pre-dialysis period in CKD 3–5 cohorts and dialysis-based studies.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; mGFR, measured GFR.
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characteristics are associated with a faster mean annual 
kidney function decline, such as the proportion of diabetes 
or males in the study population. The mean annual eGFR 
decline and the proportion of diabetes in CKD 3–5 cohorts 
were not significantly associated in meta-regression analysis 
(per 10%, β=0.06 mL/min/1.73 m2, 95% CI: −0.14, 0.27; 
Figure S2A). We should note here that there was one outlier 
with a reported mean annual kidney function decline of 
8.4 (±11.1) mL/min/1.73 m2 and only 9.2% of the population 
had diabetes.38 After exclusion of this outlier, the meta-regres-
sion analysis yielded a significant association between annual 
eGFR decline and the proportion of participants with diabetes 
in CKD 3–5 cohorts (β=0.18 mL/min/1.73 m2, 95% CI: 0.04, 
0.33; Figure S2B). This equates to a 0.18 mL/min/1.73 m2 
increase in weighted mean annual eGFR decline for every 
10% increase in the proportion of participants with diabetes. 
The mean annual eGFR decline and the proportion of males 
in CKD 3–5 cohorts were not significantly associated in 
meta-regression (per 10%, β=0.12 mL/min/1.73 m2, 95% 
CI: −0.36, 0.60). Meta-regression analysis showed that the 
mean annual eGFR decline in the pre-dialysis period was not 
clearly associated with the duration of the pre-dialysis period 
(difference=0.19 mL/min/1.73 m2, 95% CI: −0.09, 0.48) or the 
mean baseline eGFR value (difference=0.01 mL/min/1.73 m2, 
95% CI: −0.06, 0.05) in CKD 3–5 cohorts. We found an asso-
ciation between the study size and the magnitude of reported 
mean annual eGFR decline for CKD 3–5 cohorts (Egger’s 
test p value=0.002) and no clear association for dialysis-
based studies (Egger’s test p value=0.11; see  Figure S3 for 
funnel plots).
sensitivity and subgroup analysis
For CKD 3–5 cohorts, 6 studies were assessed as low risk of 
bias and 37 as high risk of bias, with a weighted mean annual 
eGFR decline of 2.6 (95% CI 2.0, 3.2) and 2.4 (2.2, 2.7) 
mL/min/1.73 m2, respectively. For dialysis-based studies, 
7 studies were assessed as low risk of bias and 10 as high 
risk of bias, with a weighted mean (95% CI) annual eGFR 
decline of 8.2 (6.5, 9.9) and 8.7 (6.8, 10.1) mL/min/1.73 m2, 
respectively. Risk of bias assessment was repeated for CKD 
3–5 cohorts using the two selection criteria applied to 
dialysis-based studies. This yielded similar weighted mean 
annual eGFR decline rates of 2.6 (95% CI: 2.3, 3.0) and 
2.4 (2.0, 2.6) mL/min/1.73 m2 for studies with low risk and 
high risk of bias, respectively. In the subgroup analysis for 
CKD stage 3a, 3b, 4 and 5, the decline rates were 1.7 (3 
cohorts; 95% CI: 1.4, 2.1), 2.4 (17 cohorts; 95% CI: 2.0, 
2.7), 2.5 (21 cohorts; 95% CI: 2.2, 2.8) and 3.0 (2 cohorts; 
95% CI: 0.8, 5.3) mL/min/1.73 m2, respectively. In a 
random-effects meta-analysis using linear mixed models 
fitted with restricted maximum likelihood, similar results 
were obtained.
Discussion
This meta-analysis showed that the reported mean annual 
eGFR decline during the pre-dialysis period is larger in 
patients from dialysis-based studies compared to that in CKD 
3–5 cohorts. We found that the weighted mean annual eGFR 
decline was 8.5 (95% CI: 6.8, 10.1) in dialysis-based studies 
compared to 2.4 (95% CI: 2.2, 2.6) mL/min/1.73 m2 in CKD 
3–5 cohorts. Importantly, CKD 3–5 cohorts are more likely 
to represent the true eGFR decline prior to dialysis, given 
the way dialysis-based studies select their patients. These 
results underline that eGFR decline estimations from CKD 
3–5 cohorts, as opposed to dialysis-based studies, should 
be used for clinical decision making in CKD 3–5 patients, 
such as in the context of anticipating treatment decisions and 
priorities, for instance, the moment to start dialysis. These 
eGFR decline estimations from CKD 3–5 cohorts should 
also be used for power calculations in randomized controlled 
Table 1 Characteristics of included CKD 3–5 cohorts and 
dialysis-based studies
Characteristics CKD 3–5 
cohorts 
(n=43)
Dialysis-
based studies 
(n=17)
Total participants 67,668 35,282
Participants per study (range) 62–26,246 63–18,874
Mean age, years (range) 42–73a 56–69
% Male (range) 42–97 53–98
% Diabetes (range) 0–100b 20–100c
Kidney function measure
 CKD-EPi 4 2
 MDrD 31 10
 Cockcroft–gault 2 1
 Other 6d 4
Mean follow-up period until dialysis 
initiation or end of follow-up, 
years (range)
0.4–8.2e 0.2–4.1f
Mean baseline egFr, ml/min/1.73 m2 
(range)
10–45g 6–35h
Notes: Data are presented as number or range. aOne study did not report mean age, 
but median without variance. bsix studies did not report % diabetes. cFour studies 
did not report % diabetes. din two studies, the used egFr measure was unclear, 
is counted as kidney function measure of the “other” category. eFor 15 studies, 
mean follow-up period was unclear (7 reported median, 6 only planned follow-up 
period, in 2 studies, follow-up period was not available for patients included in the 
meta-analysis). fFor seven studies, mean follow-up period was unclear. gFor two 
studies, mean baseline egFr was unclear. hFor seven studies, mean baseline egFr 
was unclear.
Abbreviations: CKD, chronic kidney disease; CKD-EPi, chronic kidney disease 
epidemiology collaboration; eGFR, estimated glomerular filtration rate; MDRD, 
modification of diet in renal disease.
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Study
CKD 3–5 cohorts
Barrett et al46 (2011)
Brown et al13 (2012)
Chen et al47 (2011)
Chen et al48 (2012)
Chen et al49 (2013)
Chen et al50 (2014)
Chen et al51 (2015)
Chen et al6 (2016)
Chiu et al52 (2008)
Chue et al53 (2011)
Conway et al54 (2009)
Dattolo et al55 (2016)
Drüeke et al56 (2006)
Goicoechea et al57 (2010)
De Goeij et al9 (2011)
Golper et al14 (2015)
Gouva et al58 (2004)
Halimi et al41 (2016)
Heaf and Mortensen15 (2011)
Hsieh et al59 (2017)
Inaguma et al60 (2016)
Jones et al61 (2006)
Khan et al62 (2017)
Khan et al63 (2016)
Kikuchi et al64 (2017)
Kuo et al65 (2015)
Levin et al66 (2008)
Lewis et al16 (2004)
Lim et al67 (2014)
Lin et al68 (2013)
Lucas et al38 (2008)
McCaughan et al17 (2014)
Meuleman et al39 (2015)
Nacak et al8 (2015)
Peeters et al69 (2014)
Portoles et al70 (2013)
Rigalleau et al42 (2007)
Schulman et al71 (2015)
Tan et al43 (2015)
Tangkiatkumjai et al72 (2017)
Tsai et al18 (2012)
Tsai et al73 (2016)
Subtotal (I2=99.1%, p=0.000)
Subtotal (I2=99.8%, p=0.000) 
Xie et al19 (2014)
Dialysis-based studies
Ambrogi et al12 (2009)
Beltran et al74 (2009)
Bhan et al75 (2007)
Eyre et al76 (2008)
Haapio et al77 (2012)
He et al78 (2016)
Hsu et al79 (2016)
Inaguma et al80 (2017)
Jeong et al81 (2011)
Jungers et al82 (2001)
Kitai et al7 (2015)
Maeda et al83 (2011)
O’Hare et al84 (2011)
O’Hare et al3 (2012)
Ramspek et al85 (2017)
Sumida et al11 (2017)
Sumida et al86 (2016)
n
474 1.1 (0.7, 1.5)
1.6 (1.1, 2.1)
1.6 (1.3, 1.9)
1.3 (0.9, 1.8)
2.5 (2.4, 2.6)
2.0 (1.3, 2.7)
3.2 (2.7, 3.7)
1.9 (1.6, 2.2)
3.0 (3.0, 3.0)
1.3 (0.5, 2.1)
1.4 (1.2, 1.6)
1.9 (1.7, 2.1)
3.3 (2.8, 3.8)
0.5 (–0.4, 1.4)
4.2 (3.4, 5.0)
3.2 (2.6, 3.8)
6.6 (4.8, 8.4)
3.2 (1.5, 4.9)
1.5 (1.3, 1.7)
1.7 (1.4, 2.0)
2.7 (2.3, 3.1)
3.3 (3.0, 3.6)
3.0 (3.0, 3.0)
2.5 (2.3, 2.7)
3.2 (2.7, 3.7)
3.2 (2.6, 3.8)
2.3 (2.2, 2.4)
1.6 (1.4, 1.8)
2.2 (2.1, 2.3)
1.3 (0.9, 1.7)
8.4 (7.1, 9.7)
2.1 (1.7, 2.5)
1.9 (1.5, 2.3)
1.5 (1.3, 1.7)
1.5 (1.3, 1.7)
1.0 (–0.1, 2.1)
1.5 (–1.8, 4.8)
5.2 (4.6, 5.8)
4.4 (3.9, 4.9)
1.6 (0.8, 2.4)
1.8 (1.6, 2.0)
2.8 (2.6, 3.0)
3.6 (3.6, 3.6)
2.4 (2.2, 2.6)
13.2 (13.0, 13.4)
7.0 (5.9, 8.1)
3.8 (1.5, 6.1)
8.7 (6.5, 10.9)
6.6 (6.4, 6.8)
7.1 (5.6, 8.6)
6.7 (6.5, 6.9)
13.0 (12.1, 13.9)
7.4 (6.8, 8.0)
5.8 (4.6, 8.0)
11.8 (10.8, 12.8)
8.9 (6.4, 11.4)
6.7 (6.3, 7.1)
13.5 (13.2, 13.8)
5.1 (4.6, 5.6)
12.5 (12.3, 12.7)
5.9 (5.9, 5.9)
8.5 (6.8, 10.1)
499
415
186
3,383
1,862
1,206
1,891
433
225
396
342
603
113
508
123
88
630
1,441
2,408
2,966
726
621
333
728
56
4,231
1,094
2,144
4,061
284
539
399
2,466
788
405
89
999
62
295
428
472
262,446
342
63
63
122
319
77
661
1,292
160
63
125
112
666
5,606
197
6,540
18,874
–2 0 2
Mean annual eGFR decline (mL/min/1.73m2)*
4 6 8 10 12 14 16 18
Estimate* (95% CI)
Figure 2 random-effects meta-analyses of weighted annual egFr decline during the pre-dialysis period based on CKD 3–5 cohorts or dialysis-based studies.
Notes: Weights are from random effects analysis. higher values denote higher decline rate.
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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trials with kidney disease progression in pre-dialysis CKD 
patients as a primary outcome.
To our knowledge, this is the first meta-analysis directly 
comparing the annual eGFR decline in CKD 3–5 cohorts 
and dialysis-based studies. A number of previous CKD 3–5 
cohorts reported both an overall eGFR decline and an eGFR 
decline for patients who initiated dialysis, as in dialysis-based 
studies. In these studies, the reported annual eGFR decline for 
the whole CKD population ranged between 1.5 and 2.1 mL/
min/1.73 m2, and for patients who initiated dialysis, it ranged 
between 3.9 and 7.3 mL/min/1.73 m2.15,17,18 Previous literature 
is in line with our finding that the mean annual rates of kidney 
function decline in CKD 3–5 cohorts are much lower than in 
dialysis-based studies.
CKD 3–5 cohorts comply with the definition of an 
inception cohort, in which patients are included from a well-
defined point in the course of kidney disease progression, irre-
spective of their outcome. However, in dialysis-based studies, 
patients are selected based on their outcome, that is, dialysis 
start, providing biased estimates of kidney function decline 
in CKD 3–5 patients (for more in-depth explanation of the 
inception cohort, see Supplementary material 1). An intuitive 
interpretation is that some patients in CKD 3–5 cohorts will 
only progress very slowly, or even stay stable for such a long 
period that they will never initiate dialysis. Such patients are 
not included in dialysis-based studies. This is also shown 
empirically in the Netherlands: during the first years on pre-
dialysis care, 45%–64% of CKD 4–5 patients start dialysis 
therapy; 1%–8% of these patients receive a kidney transplant 
as the first form of RRT and 5%–7% die without receiving 
any form of RRT.9,10,39,40
We should acknowledge substantial study diversity was 
present in our meta-analysis. We used different methods to 
identify sources of heterogeneity, including differences in 
risk of bias, publication bias or heterogeneity due to study 
diversity. Risk of bias assessment showed that the mean 
annual eGFR decline did not materially differ between 
studies with a low risk of bias compared to those with a 
high risk of bias, for both CKD 3–5 cohorts and dialysis-
based studies.
Surprisingly, we did not f ind a strong association 
between the proportion of diabetes and the mean annual 
eGFR decline in our meta-analysis. This could be due to 
one outlier, with only 9.2% of diabetics in the CKD popula-
tion and a mean annual rate of kidney function decline of 
8.4 (±SD 11.1) mL/min/1.73 m2.38 This high annual eGFR 
decline could be explained by the fact that the study popu-
lation comprised human immunodeficiency virus–positive 
patients and was mostly of African-American origin. Both 
human immunodeficiency virus and African-American 
descent are well-known risk factors for a greater annual 
eGFR decline.30 After exclusion of this outlier, the associa-
tion became significant, in line with our current understand-
ing of the association between diabetes and kidney function. 
Of note, in our meta-analysis, three CKD 3–5 cohorts 
comprised only diabetic CKD 3–5 patients, showing mean 
annual eGFR decline rates of 1.5, 3.2 and 4.4 mL/min/1.73 m2, 
respectively.41–43 It should be emphasized that a meta-
analysis with study-level data is not optimal to assess the 
association between variables such as diabetes and eGFR 
decline.44
A major strength of this study is that the mean annual 
eGFR decline was investigated separately and compared for 
CKD 3–5 cohorts and dialysis-based studies. Also, a large 
number of studies were included (n=60), comprising 43 
CKD 3–5 cohorts and 17 dialysis-based studies. Therefore, 
the weighted effect estimates were not influenced largely 
by random error and it was possible to examine sources of 
heterogeneity within the CKD 3–5 cohorts.
Our study has some potential limitations. First, the 
outcome kidney function decline was not always reported 
in the title or abstract, which made assessing eligibility 
cumbersome. Second, we assumed a linear decline in kidney 
function in our modeling, although it has been proposed 
in the nephrology literature that this is not necessarily the 
case.3,19,45 However, meta-regression techniques are known 
to have difficulties with correct model specification. In our 
meta-regression, we could not show an association between 
either the mean duration of the pre-dialysis period or the 
mean baseline eGFR value and the reported annual eGFR 
decline in CKD 3–5 cohorts, which suggests that the linear 
assumption is not violated. In other words, the reported 
annual eGFR decline did not significantly differ for varying 
durations of the pre-dialysis period or mean baseline eGFR 
values reported in the included cohorts. Third, publication 
bias is an issue of concern in all meta-analyses. In our 
analysis, we aimed to study the decline in eGFR, and it is 
difficult to predict what role publication bias could play 
when assessing a descriptive outcome such as eGFR. We 
found an association between study size and reported eGFR 
magnitude for CKD 3–5 cohorts, implying that publication 
bias could be present. However, in the funnel plot, no clear 
pattern is visible that studies with a smaller sample size 
tend to report smaller or larger annual eGFR decline than 
studies with a larger sample size. Finally, we did not have 
individual patient data.
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Conclusion
In summary, we showed that the reported mean annual 
eGFR decline during the pre-dialysis period is much larger 
in patients from dialysis-based studies compared to that in 
CKD 3–5 cohorts. Importantly, implications for clinical deci-
sion making with regard to the management of CKD patients 
during the pre-dialysis period and the active planning of RRT 
should be based on CKD 3–5 cohorts, due to the improper 
selection of the CKD population in dialysis-based studies.
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